← News
Stocks· May 11, 2026 at 01:05 PM
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Authored by·Editorially reviewed
Onur Erkan YıldızFounder, Financial Engineer · CMB-licensed
Higher education in Financial Engineering and Money & Capital Markets. SPK (Turkey CMB) licence. 16 years across institutional markets, research, and quant-driven analytics.
NeutralMedium impact
AI summary
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story. Blowout Quarter Meets a Methodical Rebuild Lilly’s Q1 2026 ... Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Affected symbols
AI commentary is generated from public news feeds and is not investment advice.
Related coverage
StocksMedium impactNeutral1h
Stock market concentration - a feature, not a bug - Reuters
via Reuters
StocksMedium impactNeutral2h
Virtue AI Announces Speaker Lineup for CTRL+AI Featuring Leaders From NVIDIA, Capital One, Stanford, UC Berkeley, ServiceNow, Glean, and Splunk
via Yahoo Finance
NVDA
StocksMedium impactNeutral2h
CARFAX: Nearly 7 Million Vehicles Have Unfixed Backup Camera Recalls
via Yahoo Finance
TSLA
StocksMedium impactNeutral2h
Dimensional Fund Advisors Ltd. : Form 8.3 - SPIRE HEALTHCARE GROUP PLC - Ordinary Shares
via GlobalNewswire